Rock Springs Capital
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to
Business Model: B2B
Revenue: $9.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Rock Springs Capital Information
Geographic Data
Address: 650 S Exeter St
City: Baltimore
State: MD
Zip: 21202
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$823M
Social
Crunchbase
Metrics
5,414,657Website Global Rank
1,710Website Monthly Traffic
Twitter Followers
Description
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.
Contact Phone:
+14102200129
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 5/2017 | Synlogic | Series C | 42M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 7/2021 | Vedanta Biosciences | Series D | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 6/2018 | Kaleido | Series C | 101M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 7/2021 | MiRXES | Series C | 0 |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 7/2021 | Imperative Care | Series D | 0 |
| 5/2015 | BeiGene | Series B | 97M |
| 10/2021 | Honor | Series E | 70M |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 12/2019 | Imperative Care | Series C | 0 |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 1/2022 | AvengeBio | Series A | 0 |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 12/2018 | Vedanta Biosciences | Series C | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 10/2021 | Patina | Series A | 50M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 7/2021 | dMed | Series C | 0 |
| 5/2020 | Pulmonx | Equity | 66M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 10/2020 | Honor | Series D | 140M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 12/2014 | Sagimet Biosciences | Series D | 28.5M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 9/2015 | Corvus Pharmaceuticals | Series B | 75M |
| 5/2021 | Caris Life Sciences | Private Equity Round | 0 |
| 4/2019 | Inozyme | Series A | 67.4M |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 2/2015 | Chiasma | Series E | 70M |
| 8/2020 | Freenome | Series C | 270M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 12/2021 | Freenome | Series D | 300M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 12/2017 | Allakos | Series B | 100M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 6/2015 | Clementia Pharmaceuticals | Venture Round | 0 |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 7/2015 | Translate Bio | Series B | 0 |
| 6/2020 | Everest Medicines | Series C | 310M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2016 | Vedanta Biosciences | Private Equity Round | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 2/2022 | MiRXES | Series C | 0 |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 6/2015 | Advanced Accelerator Applications | Venture Round | 25.7M |
| 6/2021 | Apollo Therapeutics | Venture Round | 139.4M |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 3/2019 | Imara | Series B | 0 |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 7/2020 | Kindbody | Series B | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2023 | Hemab | Series B | 0 |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 9/2015 | AveXis | Series D | 65M |
| 11/2020 | Acumen Pharmaceuticals | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2020 | Atea | Series D | 215M |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 11/2017 | resTORbio | Series A | 40M |
| 2/2021 | Sagimet Biosciences | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2014 | Invitae | Series F | 0 |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 3/2015 | Mersana Therapeutics | Series B | 35M |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 8/2014 | Dermira | Series C | 51M |
| 11/2018 | Aprea | Series C | 0 |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2015 | Adaptive Biotechnologies | Series F | 195M |
| 3/2020 | Immunocore | Series B | 0 |
| 12/2020 | Genesis Therapeutics | Series A | 52M |
| 6/2021 | Kindbody | Series C | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 11/2013 | TriVascular | Series E | 0 |
| 4/2014 | Adverum Biotechnologies | Series B | 55M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 7/2020 | New Horizon Health | Series E | 30M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 7/2021 | Clinipace | Venture Round | 0 |
| 11/2015 | ObsEva | Series B | 58.9M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2022 | MiRXES | Series C | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
